NCT05170048

Study to Evaluate Safety and Efficacy of EG-301 in Patients With Nonfocal Geographic Atrophy Secondary to Dry-AMD

A Phase 2, Parallel, Randomized, Open-label, Controlled Study of EG-301 150 mg Daily in Patients With Nonfocal Geographic Atrophy Secondary to Dry-AMD

• Status: Not Yet Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 90 (estimated)
• Sponsor: Evergreen Therapeutics, Inc. · Industry
• Sex: All
• Age: 50 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This is a parallel, randomized, open-label, controlled study to evaluate the efficacy and safety of oral EG-301 in patients with intermediate non-exudative (dry) age-related macular degeneration (dAMD). Ninety patients will be randomly allocated in a 2:1 ratio to one of two treatment arms for at least 6 months duration. The two treatment arms are: 1. AREDS2 supplements (Control Group, N=30) 2. AREDS2 supplements plus EG-DPMP-01 150 mg daily (Experimental Group, N=60)

Conditions

• Non-Exudative (Dry) Age-related Macular Degeneration (dAMD)

Interventions

Type	Name	Description
DRUG	EG-301	The investigation drug, EG-301 Tablets 150mg, is for oral use.
DIETARY_SUPPLEMENT	AREDS2 supplements	AREDS2 supplement is the stand of care

Timeline

• Start date: 2026-06-01
• Primary completion: 2028-06-01
• Completion: 2028-06-01
• First posted: 2021-12-27
• Last updated: 2025-12-08

Regulatory

• FDA-regulated drug study